2026. Bimekizumab Durability of High-Level Clinical and Quality of Life Responses in Early Responders with Moderate to Severe Plaque Psoriasis: 4-Year Results from Four Phase 3 Trials. SKIN The Journal of Cutaneous Medicine. 10, 3 (May 2026), s773. DOI:https://doi.org/10.25251/h6t2hj68.